Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | UBE2D3 | P61077 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | SELE | P16581 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2006340 | 0.86 | TACR1 (0.45) | KDM4CTACR1MEN1KMT2ANPC1 | |
| SCHEMBL18362480 | 0.85 | KDM4C (0.38) | KDM4CTACR1MEN1KMT2ANPC1 | |
| SCHEMBL8887331 | 0.84 | KDM4C (0.41) | KDM4CTACR1MEN1KMT2ANPC1 | |
| SCHEMBL11068192 | 0.84 | KDM4C (0.38) | KDM4CTACR1MEN1KMT2ANPC1 | |
| SCHEMBL29680564 | 0.83 | KDM4C (0.42) | KDM4CTACR1MEN1KMT2ANPC1 | |
| SCHEMBL9442675 | 0.83 | HTR6 (0.40) | KDM4CTACR1MEN1KMT2ANPC1 | |
| SCHEMBL20974574 | 0.83 | KDM4C (0.42) | KDM4CTACR1MEN1KMT2ANPC1 | |
| SCHEMBL18355699 | 0.81 | TACR1 (0.46) | KDM4CTACR1MEN1KMT2ANPC1 | |
| SCHEMBL28815981 | 0.81 | KDM4C (0.38) | KDM4CMEN1KMT2ANPC1RAB9A | |
| SCHEMBL12375131 | 0.81 | GABRA1 (0.46) | KDM4CMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476287-B2 | 3-hydroxy-5-arylisothiazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8476287-B2 | 3-hydroxy-5-arylisothiazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8476287-B2 | 3-hydroxy-5-arylisothiazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8455500-B2 | 3-hydroxy-5-arylisoxazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| US-8455500-B2 | 3-hydroxy-5-arylisoxazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| US-8455500-B2 | 3-hydroxy-5-arylisoxazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| EP-2518060-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-10-31 | — | — | EP | disclosed |
| EP-2495238-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
| EP-0543238-B1 | 3-Isoxazolylphenyl-compounds, their preparation and application | BASF AG (DE) | 1997-06-04 | — | — | EP | disclosed |
| EP-0457204-B1 | 3-Isoxazolylbenzylesters, their preparation and utilization | BASF AG (DE) | 1994-12-07 | — | — | EP | disclosed |
| EP-0414059-B1 | Dihalogenovinylbenzylesters, process and starting material for their preparation and their utilization for the control of parasites | BASF AG (DE) | 1993-10-27 | — | — | EP | disclosed |
| US-5256666-A | Pesticides | BASF AKTIENGESELLSCHAFT (DE) | 1993-10-26 | — | — | US | disclosed |
| EP-0543238-A1 | 3-Isoxazolylphenyl-compounds, their preparation and application | BASF Aktiengesellschaft (DE) | 1993-05-26 | — | — | EP | disclosed |
| US-5151441-A | Insecticides or miticides | BASF AKTIENGESELLSCHAFT (DE) | 1992-09-29 | — | — | US | disclosed |
| EP-0457204-A1 | 3-Isoxazolylbenzylesters, their preparation and utilization | BASF Aktiengesellschaft (DE) | 1991-11-21 | — | — | EP | disclosed |
| EP-0414059-A1 | Dihalogenovinylbenzylesters, process and starting material for their preparation and their utilization for the control of parasites | BASF Aktiengesellschaft (DE) | 1991-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | KDM4C 3758/4885TACR1 326/4885MEN1 3552/4885 |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | KDM4C 3404/4885TACR1 281/4885MEN1 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.